Annales pharmaceutiques francaises · 2026
Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping - scoping review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Henriques João Pedro, Weckwerth Artur Villas Boas, Santana Adriana Campos Passanezi, Damante Carla Andreoti, Santos Carlos Ferreira Dos, Negrato Carlos Antonio
Аннотация
OBJECTIVES: Diabetes mellitus and periodontal disease are highly prevalent chronic disorders linked by bidirectional inflammatory and oxidative pathways. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging pharmacologic agents with anti-inflammatory properties that may benefit periodontal tissues, although the available evidence remains limited. This scoping review aimed to map the available evidence on the effects of GLP-1 RA on periodontal tissues and their underlying mechanisms of action.
METHODS: Following the Joanna Briggs Institute methodology and the PRISMA-ScR extension, a systematic search was conducted across PubMed/MEDLINE, Web of Science, Scopus, Embase, LILACS, and the Cochrane Library for studies evaluating the impact of GLP-1 RA in periodontal models or tissues, without date restriction. Records were screened against predefined eligibility criteria, and data were charted using a structured extraction form.
RESULTS: Seven studies, published between 2015 and 2022, met the inclusion criteria: three animal studies, three in vitro studies, and one mixed-design study; no clinical trial was identified. Liraglutide was the most studied agent (four out of seven studies). GLP-1 RA were associated with reduced pro-inflammatory signalling, attenuated alveolar bone resorption, and enhanced osteogenic differentiation, frequently through NF-κB/MAPK and Wnt/β-catenin pathways. One study showed reduced inflammatory markers without reduced bone loss.
CONCLUSION: Current evidence is exclusively preclinical, conducted predominantly with liraglutide, and insufficient to support any therapeutic indication. These findings identify a biologically plausible hypothesis that warrants strict future clinical investigation.
METHODS: Following the Joanna Briggs Institute methodology and the PRISMA-ScR extension, a systematic search was conducted across PubMed/MEDLINE, Web of Science, Scopus, Embase, LILACS, and the Cochrane Library for studies evaluating the impact of GLP-1 RA in periodontal models or tissues, without date restriction. Records were screened against predefined eligibility criteria, and data were charted using a structured extraction form.
RESULTS: Seven studies, published between 2015 and 2022, met the inclusion criteria: three animal studies, three in vitro studies, and one mixed-design study; no clinical trial was identified. Liraglutide was the most studied agent (four out of seven studies). GLP-1 RA were associated with reduced pro-inflammatory signalling, attenuated alveolar bone resorption, and enhanced osteogenic differentiation, frequently through NF-κB/MAPK and Wnt/β-catenin pathways. One study showed reduced inflammatory markers without reduced bone loss.
CONCLUSION: Current evidence is exclusively preclinical, conducted predominantly with liraglutide, and insufficient to support any therapeutic indication. These findings identify a biologically plausible hypothesis that warrants strict future clinical investigation.